These celebs went to college and earned their degrees
These celebs went to college and earned their degrees
Poland started administering Johnson & Johnson COVID-19 shots on Thursday as benefits from the vaccine outweigh potential risks, government and drug office representatives said. U.S. federal health agencies on Tuesday recommended pausing use of Johnson & Johnson's vaccine for at least a few days after six women under age 50 developed rare blood clots after receiving the shot, dealing a fresh setback to efforts to tackle the pandemic. The head of the Office for Registration of Medicinal Products told the conference that benefits from the J&J vaccine outweigh potential risks.
The two said in a joint statement that they are “better as friends” and will continue to support each other in their shared ventures.
The "Paroxysmal Nocturnal Hemoglobinuria - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
NAV CANADA announced today its traffic figures for the month of March 2021, as measured in weighted charging units for enroute, terminal and oceanic air navigation services, in comparison to the last fiscal year.
Poster presentation on BION-1301 including Gd-IgA1 biomarker data in healthy volunteers from Parts 1 and 2 of the ongoing phase 1b study of BION-1301 and data from the phase 1 IV to SC bioavailability study in healthy volunteers Poster presentation on atrasentan’s effect to rapidly reduce albuminuria and downregulate intra-renal transcriptional proliferative, inflammatory and fibrotic signaling in the gddY mouse IgAN modelPoster presentation on atrasentan’s effect to attenuate human renal mesangial cell activation induced by endothelin-1 or IgAN patient immune-derived immune complexes in a translational model systemTwo informational poster presentations on the phase 3 ALIGN trial design for atrasentan in IgA nephropathy (IgAN) and the phase 2 AFFINITY trial design for atrasentan in proteinuric glomerular diseasesEncore poster presentation on CHK-336, a first-in-class oral small molecule lactate dehydrogenase A (LDHA) inhibitor with the potential to treat all subtypes of primary hyperoxaluria (PH) and other disorders arising from excess oxalate SEATTLE, April 15, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced six poster presentations at the ISN World Congress of Nephrology 2021 (WCN ’21). “The depth and breadth of our presence at this year’s WCN ’21 is a testament to Chinook’s role as a leading kidney disease company,” said Eric Dobmeier, president and chief executive officer of Chinook. “Our data demonstrating BION-1301’s ability to significantly reduce Gd-IgA1 levels in healthy volunteers, as well as the favorable pharmacodynamics of subcutaneous administration of BION-1301, position the program well to move forward in demonstrating its disease-modifying potential for IgA nephropathy patients. In addition, our preclinical poster presentations on atrasentan provide broader insights into its anti-fibrotic and anti-inflammatory properties that are additive and complementary to its proteinuria-lowering mechanism of action.” WCN21-0706: A Phase 1, Open Label, Randomized, Single Dose, Parallel Group Safety and Bioavailability Study of BION-1301 Administered by Intravenous (IV) and Subcutaneous (SC) Routes BION-1301 is a novel anti-APRIL monoclonal antibody currently in phase 1 clinical development for IgAN. Blocking APRIL is a potential disease-modifying approach to treating IgAN by reducing circulating levels of Gd-IgA1 to prevent the formation of immune complexes that deposit in the glomeruli of the kidney, causing damage. The ongoing phase 1 multi-center trial (see www.clinicaltrials.gov, identifier NCT03945318) evaluated the safety and tolerability of BION-1301 in 63 healthy volunteers in double-blinded, placebo-controlled single-ascending dose (SAD) and multiple-ascending dose (MAD) settings. Healthy volunteers in the SAD portion of the study received placebo or a single intravenous (IV) dose of BION-1301 ranging from 10 mg to 1350 mg on day 1. Healthy volunteers in the MAD portion of the study received placebo or IV doses of BION-1301 ranging from 50 mg to 450 mg on days 1, 15 and 29 (three doses total). As previously presented, BION-1301 was well-tolerated with no serious adverse events (SAEs), a pharmacokinetic (PK) half-life of approximately 33 days and demonstrated dose-dependent pharmacodynamic (PD) effects characterized by durable reductions in serum levels of IgA and IgM, with a lesser reduction in IgG. Recently analyzed data from this study in healthy volunteers also demonstrated that BION-1301 produced dose-dependent reductions in serum Gd-IgA1 levels that were greater in magnitude than previously reported for total IgA concentrations. In the MAD cohort, BION-1301 reduced Gd-IgA1 levels by 39%, 51% and 55% on Day 29 following the first two doses but prior to the third dose of BION-1301 at 50 mg, 150 mg and 450 mg, respectively, compared to a mean 6% increase in Gd-IgA1 in the placebo group. Upon further follow-up on Day 85, which was 56 days after the third and final dose of BION-1301, Gd-IgA1 reductions were sustained, with mean reductions of 24%, 48% and 70%, at 50 mg, 150 mg and 450 mg, respectively, compared to a mean 4% increase in Gd-IgA1 in the placebo group. Data figures from Day 85 were not included in the poster presentation, but can be found in Chinook’s corporate presentation located on the Events and Presentations section of Chinook’s website. Part 3 of the phase 1 study is ongoing to evaluate BION-1301 in adult IgAN patients in an open-label setting. Preliminary data from Part 3 will be presented at nephrology conferences in 2021. With the aim to reduce patient burden with a more convenient alternative administration route, BION-1301 was further studied in a single-dose phase 1 study to determine safety and bioavailability of BION-1301 administered via IV infusion or SC injection in healthy volunteers. This was a phase 1, open-label, randomized, parallel group, safety and bioavailability study of 300 mg BION-1301 administered intravenously or subcutaneously to adult healthy volunteers in the United States. Key highlights from the bioavailability study include the following: BION-1301 was well tolerated when administered by both IV and SC routes in healthy volunteers, and no injection site or infusion-related reactions were reported.The PK profile of BION-1301 was consistent with previous clinical studies and minimal differences in drug concentration were observed between administration routes after one week, following the absorption phase.After SC administration, BION-1301 absorption rate was typical of a monoclonal antibody with bioavailability of approximately 50%.Magnitude of pharmacodynamic responses were largely retained with SC dosing compared to IV dosing: SC administration generated approximately 81% of the maximum free APRIL reduction;SC administration generated approximately 75% of the maximum IgA reduction. No anti-drug antibodies (ADAs) were observed in the SC cohort Data generated in this study will be used to enable SC administration of BION-1301 in ongoing and future clinical studies. WCN21-0358: Selective ETA Antagonist Atrasentan, Rapidly Reduces Albuminuria and Downregulates Intra-renal Pro-Inflammatory and Pro-Fibrotic Transcriptional Networks in the g-ddY Mouse Model of Spontaneous IgA Nephropathy The effect of short-term treatment of selective ETA antagonist atrasentan was investigated in gddY mice, a spontaneous and accelerated model of IgAN. Four days of treatment with atrasentan reduced urinary albumin to creatinine ratio (UACR) from baseline by 28%, 62% and 63% at 10 mg/kg/day, 20 mg/kg/day and 30 mg/kg/day, respectively. This effect was statistically significant at the two higher doses. Five days of treatment with atrasentan demonstrated dose-dependent effects on intra-renal gene expression profiles, assessed by RNA sequencing analysis of the kidney cortex. Gene set enrichment analysis (GSEA) to define hallmark pathways was performed and cross-validated to the transcriptome of kidney biopsy samples from publicly available IgAN patient datasets. In the biopsies of patients with IgAN, the gene pathways found to be dysregulated in the glomeruli included a down-regulation of oxidative metabolism and up-regulation of gene pathways associated with proliferation, inflammation and fibrosis. GSEA showed that treatment with 30 mg/kg of atrasentan in gddY mice consistently reversed the gene pathways found to be dysregulated in IgAN patients. The dynamic transcriptional changes in the kidney, following only five days of treatment and prior to sustained long-term reductions in albuminuria and blood pressure that could mediate this benefit, are consistent with direct anti-inflammatory and antifibrotic effects of ETA blockade in IgAN. These results support the therapeutic potential of atrasentan in IgAN to reduce proteinuria and kidney inflammation and fibrosis, key drivers of IgAN progression. WCN21-0398: Human Renal Mesangial Cell Activation Induced by Endothelin-1 or IgA Nephropathy Patient Immune Derived Complexes is Blocked by Selective ETA Antagonist Atrasentan Human renal mesangial cell (HRMC) activation is considered the initiating intra-renal event in the pathogenesis of IgAN and occurs in response to the deposition of pathogenic galactose-deficient IgA (Gd-IgA)-containing immune complexes. This activation results in increased cellular proliferation and inflammatory cytokine secretion. The role of ETA receptor activation in HRMC activation in response to endothelin-1 (ET-1) and IgAN patient-derived immune complexes was investigated. ET-1 resulted in increased HRMC proliferation and IL-6 secretion, which was blocked by atrasentan in a concentration-dependent manner. RNA sequencing and gene set enrichment analysis of HRMCs following treatment with ET-1 identified upregulation of cell proliferation, pro-fibrotic and pro-inflammatory pathways, which were reversed with atrasentan treatment. HRMCs cultured with purified IgA-containing immune complexes isolated from IgAN patient serum, had five-fold higher proliferation compared to treatment with IgA-complexes from matched healthy controls. Atrasentan significantly attenuated the proliferation induced by IgAN patient-derived IgA-containing immune complexes. Exogenous ET-1 directly stimulates mesangial cell activation, inducing proliferative, pro-inflammatory and pro-fibrotic pathways, which can be blocked by atrasentan. Atrasentan prevented HRMC hyperproliferation in response to IgAN patient-derived immune complexes. This suggests that the autocrine action of endogenously produced ET-1 on ETA receptors contributes to mesangial cell activation resulting from pathogenic IgA-containing immune complexes. These results support the therapeutic potential of atrasentan in patients with IgAN, not only via its well characterized effect of reducing proteinuria, but also by potentially reducing mesangial cell activation, a hallmark of IgA nephropathy. WCN21-0848: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients with IgA Nephropathy (The ALIGN Study) The ALIGN Study (see www.clinicaltrials.gov, identifier NCT04573478) is a global, randomized, multicenter, double-blind, placebo-controlled phase 3 clinical trial comparing the efficacy and safety of atrasentan versus placebo in patients with IgAN at risk of progressive loss of kidney function. Approximately 320 patients with biopsy-proven IgAN will be randomized to receive 0.75 mg atrasentan or placebo as a once-daily oral pill for approximately 2.5 years. Patients will continue receiving an optimized and stable dose of a RASi as standard of care. The study will also include patients that are unable to tolerate RASi therapy. The primary efficacy endpoint of the ALIGN Study is to evaluate the effect of atrasentan versus placebo on proteinuria as measured by urine protein to creatinine ratio (UPCR) from baseline to 24 weeks. Secondary and exploratory objectives include evaluating the change in kidney function over time as measured by eGFR, safety and tolerability, as well as quality of life. Chinook expects to report top-line data from the 24-week primary endpoint efficacy analysis in 2023. WCN21-0717: Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study) The AFFINITY Study (see www.clinicaltrials.gov, identifier NCT04573920) is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function. Four initial cohorts will consist of patients with: IgAN with UPCR of 0.5 to less than 1.0 g/g, focal segmental glomerulosclerosis (FSGS), Alport syndrome and diabetic kidney disease (DKD) in combination with an SGLT2 inhibitor. Additional cohorts may be added to the study over time. Approximately 20 patients will be enrolled in each cohort to receive 0.75 mg atrasentan for 52 weeks. Patients in all cohorts will continue receiving an optimized and stable dose of a RAS inhibitor as standard of care. The AFFINITY Study will enroll patients in the United States, Australia, South Korea, the United Kingdom, Italy and Spain. The primary efficacy endpoint of the AFFINITY Study is the effect on proteinuria as measured by UPCR in patients with IgAN, FSGS and Alport syndrome and the change in albuminuria as measured by urine albumin to creatinine (UACR) in patients with DKD, from baseline to 12 weeks. Chinook expects to report data from initial cohorts of patients in the AFFINITY Study during 2022. WCN21-0612: Discovery of CHK-336: A First-in-Class, Liver-Targeted, Small Molecule Inhibitor of Lactate Dehydrogenase for the Treatment of Hyperoxaluria CHK-336, is a first-in-class, liver-targeted oral small molecule LDHA inhibitor for the treatment of PH. LDHA catalyzes the final step in the production of oxalate in the liver, and therefore LDHA inhibition has the potential to treat all forms of PH – PH1, PH2 and PH3 – as well as other disorders arising from excess oxalate. As previously presented, CHK-336 demonstrates sub-nM enzyme potency and a cellular IC50 in hepatocytes across multiple species ranging from 50 to approximately 300 nM. CHK-336 demonstrates tight LDHA binding and a very slow enzyme off-rate, to extend the duration of action and enable the potential of once-daily dosing in humans. CHK-336 was engineered with a liver-targeted distribution profile to effectively block hepatic oxalate synthesis while minimizing systemic exposures. CHK-336, dosed orally, once-daily, produced significant reductions in urinary oxalate in a mouse model of PH1, with the majority of CHK-336-treated mice reaching the normal range seen in wild-type mice. The non-clinical safety assessment of CHK-336 supports continued development and CHK-336 is currently progressing through IND-enabling GLP studies with IND submission planned for late 2021/early 2022. About Chinook Therapeutics, Inc.Chinook Therapeutics, Inc. is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1b trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com. Cautionary Note on Forward-Looking Statements Certain of the statements made in this press release are forward looking, including those relating to Chinook’s business, future operations, advancement of its product candidates and product pipeline, clinical development of its product candidates, including expectations regarding timing of initiation and results of clinical trials. In some cases, you can identify these statements by forward-looking words such as “may,” “will,” “continue,” “anticipate,” “intend,” “could,” “project,” “expect” or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, including initiation of clinical trials, whether results of early clinical trials or preclinical studies, such as those described in this press release, will be indicative of the results of future trials, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that may be more advanced or have greater resources than we do, our ability to obtain and adequately protect intellectual property rights for our product candidates and the effects of COVID-19 on our clinical programs and business operations. Many of these risks are described in greater detail in our filings with the SEC. Any forward-looking statements in this press release speak only as of the date of this press release. Chinook assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact:Noopur LiffickVice President, Investor Relations & Corporate Communicationsinvestors@chinooktx.com email@example.com
Sawyer recognized as a leading entrepreneur and philanthropist throughout the Greater Bangor, Maine area and nationwide Entrepreneur and philanthropist Waldron “Tom” Sawyer, Jr. will receive an honorary doctorate of business administration from Husson University, one of the nation's leading professional educators, on Saturday, May 8, 2021. In addition to recognizing Sawyer’s dedication to the community, this honorary degree pays tribute to Sawyer’s 34 years of service to the University. The Husson University Commencement ceremony for graduate students will take place outdoors at 10 a.m. on Saturday, May 8, 2021 at the Winkin Sports Complex on the University's Bangor campus. Sawyer will receive his honorary doctorate of business administration as part of this event. Honorary degrees are the highest honor Husson University can bestow. BANGOR, MAINE, April 15, 2021 (GLOBE NEWSWIRE) -- After the announcement by Governor Mills that COVID-19 restrictions on public gatherings would be relaxed, Husson University decided to move forward with two traditional Commencement exercises this year. The Commencement ceremony for graduate students will take place outdoors at 10 a.m. on Saturday, May 8, 2021 at the Winkin Sports Complex. Undergraduate students will begin their graduation exercises at 2 p.m. that day at the same location. The highlight of the morning’s Commencement ceremony will be when Husson University pays special tribute to Waldron “Tom” Sawyer, Jr., by awarding him an honorary doctorate of business administration. Sawyer first joined the Husson Board of Trustees in 1987 and has been an active contributor to the success of the University ever since. In addition to recognizing Sawyer’s dedication to entrepreneurship and philanthropy, this honorary degree pays tribute to Sawyer’s 34 years of service to the University. “The W. Tom and Bonnie Sawyer Library here on our Bangor campus would not have been possible without Tom’s generosity of spirit and his dedication to serving the greater Bangor community,” said Robert A. Clark, PhD, CFA, president of Husson University. “His business prowess, commitment to social responsibility and our state make him more than deserving of this high honor.” Assisting with the hooding of the honorary degree recipient will be John Rohman, chair of the Husson University Board of Trustees. “Honorary degrees are the highest honor Husson University can bestow. The selection of Tom as this year’s honorary degree recipient is certainly fitting,” said Rohman. “He has tirelessly supported numerous causes and organizations in our area. Both respected and liked, he is one of those people who helps make the world a better place.” Born and raised in Bangor, Maine, Waldron “Tom” Sawyer, Jr. graduated from Bangor High School and earned his bachelor's degree in education from the University of Denver in 1972. He is recognized as a leading entrepreneur and philanthropist throughout the Greater Bangor area and nationwide. Sawyer owned several businesses. They included the Sawyer Environmental Recovery Facility, the Breakwater 1904 Inn (1991-1998), the Pine Tree Landfill (1974-1996), and the Southwest Harbor Boat Marina (1993-1998). As a successful business owner, he has also helped develop the potential of others by successfully investing in projects and businesses including the Bangor Historic Raceway and the Turtle Head Marina. Tom has contributed his time and energy to many boards and organizations. These include the Maine Businesses for Social Responsibility, the Anah Highlanders (Drum Major), and the Maine Community Foundation Board of Directors. Sawyer has also served as an honorary trustee of the Jackson Laboratory, and an officer in the Penobscot Bay Sail and Power Squadron. Other area organizations he has helped to support include: The United Way of Eastern MaineThe Bangor YMCAGreater Bangor Chamber of Commerce (11 years)Maine Community Foundation (9 years)Eastern Maine Development CorporationPenobscot Maritime MuseumMaine Employers' Mutual Insurance CompanyBangor JayceesBangor Rotary ClubMaine Blue Cross & Blue Shield (10 years)Merrill BanksharesMaine Public Policy InstituteMaine Robotics (17 years)Action Committee of 50Bangor Target Area Development CorporationJohn Bapst Memorial High School FoundationMaine Economic Growth CouncilMaine Public Policy Institute His professional accomplishments are numerous. Sawyer was a member of the Bangor City Council from 1986-1993 and a Bangor Education Foundation member from 1987-1994. He also served as the Mayor of Bangor in 1989 and was a Maine State Senator from 2000-2004. Sawyer was named the vice chair of the Husson University Board of Trustees in 1987 and was awarded an honorary bachelor’s degree that same year. He was elected chair of the Board of Trustees in 2004, and served in that capacity for two years. In 1990, the U.S. Small Business Administration awarded Sawyer the National SBA Entrepreneurial Success Award and the Entrepreneur of the Year Award. He was also inducted into the organization’s Hall of Fame. In 2002, he was named a Maine Audubon Wildlife Conservation Champion. Other honors bestowed upon Sawyer include: Phi Delta Kappa, Education Honor Society, Denver University, 1970Granville B. Johnson Award in Education, Denver University, 1972Newcomen Society for Study of History of Engineering & Technology Inductee, 1988Who's Who in Finance & Industry, 1991 & 1993Hall of Fame Inductee, Bangor YMCA, 1997Honorary 33rd Degree, Scottish Rite, 2000Honorary Class Spokesman, Maine Development Foundation's Leadership Maine, ETA Class, 2000Husson Chief Award, 2001Sigma Beta Delta, International Honor Society in Business Management, Husson College, 2002Honorary Associate of Science in Communications, NESCom, 2003Who's Who in American Politics, 2004-2005Chesley H. Husson, Sr. Award, Husson College, 2005 Sawyer is recognized as a Master U.S. Merchant Marine Officer and holds a 100-ton Master's License. He is also a Flotilla Commander for the United States Coast Guard Auxiliary. Sawyer is proud to serve his country and continues to be an active member of the Auxiliary. He is also a past squadron commander for the U.S. Power Squadron, and has raced his own schooner to Bermuda four times. Never one to stray far from the sea, Sawyer is also the owner of a 39-foot yacht called the “Dirigo Pilot.” He currently lives in Florida with his wife, Bonnie. The couple has two children, Shannon and Patricia, and three grandchildren. Bonnie Sawyer is a retired Major in the Army Nurse Corps. Due to the ongoing COVID-19 pandemic, students will be only allowed to invite two guests. Anyone who cannot be present at Husson’s Commencement exercises will be able to watch a streaming video of the event available at Husson.edu on the day of the event. This includes the honorary degree presentation to Waldron “Tom” Sawyer, Jr. For more than 120 years, Husson University has shown its adaptability and strength in delivering educational programs that prepare future leaders to handle the challenges of tomorrow through innovative undergraduate and graduate degrees. With a commitment to delivering affordable classroom, online and experiential learning opportunities, Husson University has come to represent a superior value in higher education. The hallmarks of a Husson education include advanced knowledge delivered through quality educational programs. According to a recent analysis of tuition and fees by U.S. News & World Report, Husson University is one of the most affordable private colleges in New England. For more information about educational opportunities that can lead to personal and professional success, visit Husson.edu. # # # Attachments Tom_Sawyer - 2 husson commencement 2010843-3 CONTACT: Eric B. Gordon Husson University 207.649.4647 firstname.lastname@example.org
The "Calibration Services Markets. Strategies and Trends with Forecasts by Type of Calibration, by Industry and by Country. Includes Custom Analysis and World Metropolitan Area Market Sizes. 2021 to 2025" report has been added to ResearchAndMarkets.com's offering.
"Global C5 Compliment Inhibitors Drug Market Opportunity, Drug Price, Sales & Clinical Trials Insight 2026" Report Highlights:
The modern ACH Network saw volume soar in the first quarter of 2021, setting two new records in the process.
PCT LTD (OTC Pink: "PCTL"), reported financial results for the fiscal year ended December 31, 2020.
Version2, an industry leader in programmatic advertising and technologies, celebrates its milestone first anniversary. The company launched during the onset of the COVID-19 global pandemic in 2020. This month marks consecutive growth and expansion, serving more than 50 clients both domestically and internationally.
The "Topical Pain Relief Market" report has been added to ResearchAndMarkets.com's offering.
Bank of America earnings easily beat views amid loan-loss reserves released and strong investment banking. Citigroup also topped views.
The onychomycosis market estimated to be valued at USD USD 2730. 72 million in 2020 and is expected to reach approximately USD 3781. 42 million in 2026, registering a CAGR of nearly 5. 75% during the forecast period.New York, April 15, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Onychomycosis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" - https://www.reportlinker.com/p06062858/?utm_source=GNW Prior to the COVID-19 pandemic, clinical examination, dermoscopy, and mycological examination were recommended for all patients with suspected onychomycosis. However, with the spread of the COVID-19 pandemic, non-urgent in-person visits are being deferred, and telemedicine may be utilized to address some aspects of onychomycosis diagnosis and treatment. Telemedicine may be appropriately utilized to assess patients with suspected onychomycosis, but it is better optimized for patients with prior mycological confirmation.Hence, the market is expected to witness a short-term disruption due to the COVID-19 pandemic. However, the revenue growth rate is expected to recover during the forecast period, and the global onychomycosis market is estimated to digit growth trajectory.Onychomycosis, also known as tinea unguium, is a fungal infection of the fingernails or toenails that may involve any component of the nail unit, including the matrix, bed, or plate. This may cause pain, disfigurement, and discomfort and may produce serious issues, and results in reducing the quality of life. Onychomycosis is of different types such as superficial onychomycosis, distal and lateral subungual onychomycosis, proximal subungual onychomycosis, endonyx onychomycosis, and total dystrophic onychomycosis. Onychomycosis accounts for one-third of fungal skin infections because only about one-half of nail dystrophies are caused by fungus.Increasing the geriatric population, rising prevalence of onychomycosis, and diabetic population worldwide and growing awareness about the potential threats of onychomycosis are the key driving factors in the onychomycosis treatment market.In addition, according to the United Nations Department of Economics and Social’s 2019 report, by 2050, 1 in 6 people around the world will be over the age of 65 (16%), up from 1 in 11 people in 2019 (9%). By 2050, 1 in 4 persons living in Europe and North America could be aged 65 years or above. The number of persons aged 80 years and above is projected to triple, from 143 million in 2019 to approximately 426 million in 2050.?Key Market TrendsThe Drugs Segment is Expected to Hold a Major Market Share in the Onychomycosis Treatment MarketSome of the drugs available for the treatment of onychomycosis are terbinafine, ciclopirox, Jublia, fluconazole, Penlac, Ciclodan, ketoconazole, Sporanox, itraconazole, Kerydin, efinaconazole, griseofulvin, and so on. For onychomycosis treatment, drugs remain the first-line choice of treatment with major market share owing to a consistently high success rate.As per Elewski and Charif onychomycosis report, states that approximately 40% of the elderly population have onychomycosis. Moreover, a reduction in nail growth rate ranges from about 40% to 60% in persons more than 65 years of age. Furthermore, onychomycosis affects approximately 2% to 26% of different populations globally. Moreover, less than 30% of infected individuals with onychomycosis seek medical advice or treatment in developed countries.The drugs segment holds a significant market share in the onychomycosis treatment market and is anticipated to show a similar trend over the forecast period due to the highly effective and easy availability of the products. In February 2019, Moberg Pharma entered into a license agreement granting the Consumer Health division of Bayer exclusive European rights to MOB-015, a new topical treatment of onychomycosis based on Moberg’s patented proprietary formulation of terbinafine. Bayer will be marketing, distributing, and selling MOB-015 in Europe upon completion of Phase III clinical development and registration.Morover, with the COVID 19 pandemic, distribution of the drugs has been disrupeted all over the world due to the supply chain disruptions and expected to have impact in 2020, however, in late 2020 , 2021 and further years, market is for onychomycosis expected to recover and expected to show positive growth over the period.North America is Expected to Hold a Significant Share in the Market in the Forecast PeriodNorth America is expected to hold a major market share in the global onychomycosis treatment market due to high drug costs, rising geriatric population, increasing prevalence of onychomycosis, and diabetic patient population in this region. According to the United States Census Bureau 2019 Population Estimates, the 65-and-older population grew by 3.2% (1,688,924) from 2018 to 2019 to reach over 54 million. In people aged 65 years and older, the prevalence of diabetes was found to be 26.8% (total diabetes prevalence).The reasons for the age-related increase in onychomycosis include a variety of factors, like repeated nail trauma, poor peripheral circulation, diabetes, suboptimal immune function, longer exposure to pathogenic fungi, inactivity, or the inability to cut the toenails or maintain good foot care. Various strategies, such as research and development, mergers and acquisitions, and product launches, are being adopted by domestic companies to strengthen their market position.In October 2020, United States-headquartered Pfizer Inc. announced that it had begun clinical studies concerning onychomycosis. The first one involved a study in determining whether the AN2690 topical solution is an effective treatment for onychomycosis of the toenail. The second one was an open-label study to evaluate the safety and pharmacokinetics of tavaborole 5% topical solution to treat distal subungual onychomycosis of the toenail in both children and adolescents.On the other hand COVID 19 pandemic has resulted decreased diagnosis and impacted the sales revenue of drugs and other treatment methods for onychomycosis as there is focus of hospitals and primary care centers for COVID 19 patients .Competitive LandscapeThe onychomycosis treatment market is fragmented competitive and consists of several major players. Companies are focusing on developments, collaborations, new product launches and to strengthen their market position. For instance, In April 2020, the United States Food and Drug Administration expanded the approval of Jublia manufactured by Bausch Health. Jublia is a topical solution use in the treatment of onychomycosis of the toenail(s) in patients aged six years and above.Some of the players which are currently dominating the market are Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.), Galderma SA, Novartis AG, Pfizer Inc., Moberg Pharma AB, Johnson & Johnson, Bayer AG, Dr. Reddy’s Laboratories Ltd, Cipla Ltd, Medimetriks Pharmaceuticals Inc., and Lumenis Ltd.Reasons to Purchase this report:- The market estimate (ME) sheet in Excel format- 3 months of analyst supportRead the full report: https://www.reportlinker.com/p06062858/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
Nvidia and Dow Jones stock UnitedHealth were among the leaders rising near buy points as stock futures gained ahead of weekly jobless claims data.
On April 20, in a joint effort with the nonprofit World Vasectomy Day (WVD), expert vasectomy physician of SimpleVas Clinic, Dr. Esgar Guarín, will be rolling out the very first Mobile Vasectomy Clinic in the United States, as part of the celebration of Earth Day.
Today Acorio announced several key changes and promotions in their client delivery organization to better serve customers at scale.
Dublin, April 15, 2021 (GLOBE NEWSWIRE) -- The "Silicon on Insulator Market by Wafer Size, Wafer Type, Technology, Product and Application: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering. The global silicon on insulator market size was $1.11 billion in 2019, and is projected to reach $3.18 billion by 2027, growing at a CAGR of 14.1% from 2020 to 2027. Silicon on insulator technology states the usage of layered silicon-insulator-silicon substrate in position of traditional silicon in semiconductor manufacturing work. This technology is compatible with presently used fabrication process in the industry without retooling or extra equipment of existing factory. There are several benefits of silicon on insulator technology such as high performance, power saving, reduced leakage, absence of latchup, compatibility, and ease in scaling.Silicon on insulator (SoI) is an integral part of consumer electronics products such as tablets, smartphones, wearable devices, electric cars, and others. Thus, demand for SoI is increasing rapidly in consumer electronics. Also, the need for reducing power consumption in a variety of mobile and portable devices has fueled the demand for SOI devices in the consumer electronic industry.Further, the SoI wafers offer the reliability, speed, and hardness beyond traditional technologies, which increases the overall operational performance at low voltage, which is further expected to contribute to the silicon on insulators market growth. Silicon on insulator catches lot of attention in the design of high-performance circuits. In recent times, chipmakers giants such as Advanced Micro Devices, IBM and Intel Corporation have taken surging interest in the commercialization of SOI technology.The minor restructuring in the current chip fabrication methods has enabled several manufactures to shift from the bulk silicon technology to the SOI-based devices. However, the self-heating effects in SOI-based devices act as restraints to the growth of the silicon on insulator market. Moreover, the market players faced challenges in procuring the raw material and delivering the finished goods with the interrupted supply chain.The silicon on insulator market is segmented on the basis of wafer size, wafer type, technology, product, application, and region. The wafer size segment includes 200 mm and 300 mm wafers. Based on wafer type, the market is divided into RF-SOI, FD_SOI, PD-SOI, and others. By Technology, the market is segmented into BESOI, SiMOX, Smart Cut, ELTRAN, and SoS. By product, the silicon on insulator market bifurcated into optical communication, image sensing, MEMS, power, and RF FEM. By application, the market is segmented into datacom & telecom, automotive, consumer electronics, industrial, photonics, and others.By region, the silicon on insulator market trends are analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America is studied across the U.S., Mexico, and Canada. Europe is analyzed across the UK, Germany, France, Russia, and the rest of Europe. The countries covered under Asia-Pacific are China, Taiwan, Japan, South Korea, and rest of Asia-Pacific, while LAMEA includes Latin America and Middle East & Africa. In addition, the report covers country-wise cross-sectional analysis of the products and industry vertical segments.The key players profiled in the report include GlobalWafers, NXP Semiconductors, SUMCO CORPORATION, Shin-Etsu Chemical Co., Ltd., MagnaChip Semiconductor Corp, STMicroelectronics, Soitec SA, Simgui, Tower Semiconductor Ltd. (ToweJazz), and Murata Manufacturing Co. Ltd. These key players have adopted various strategies, such as product portfolio expansion, mergers & acquisitions, agreements, geographical expansion, and collaborations, to enhance their position in the silicon on insulator industry. Key Topics Covered: Chapter 1: Introduction1.1. Report description1.2. Key benefits for Stakeholders1.3. Key Market Segments1.4. Research methodology1.4.1. Primary research1.4.2. Secondary research1.4.3. Analyst tools and modelsCHAPTER 2: Executive summary2.1. CXO perspectiveCHAPTER 3: MARKET OVERVIEW3.1. Market definition and scope3.2. Key findings3.2.1. Top impacting factors3.2.2. Top investment pockets3.3. Porter's five forces analysis3.4. Market dynamics3.4.1. Drivers22.214.171.124. Surge in usage of SoI wafers in consumer electronics126.96.36.199. Enhances operational performance with low operating voltage188.8.131.52. Increasing investments by wafer manufacturers and foundry players in emerging economies3.4.2. Restraint184.108.40.206. Self-heating effects in SoI based devices3.4.3. Opportunities220.127.116.11. Increasing use of SoI technology in IoT devices and applications18.104.22.168. Implementing automation solutions across the retail industry to avoid human intervention3.4.4. Challenges22.214.171.124. Volatility in cost of raw materials3.5. COVID-19 impact analysis3.5.1. Impact on market size3.5.2. End user trends, preferences, and budget impact3.5.3. Parent industry impactCHAPTER 4: silicon on insulator Market, By wafer size4.1. Overview4.2.200 mm4.2.1. Key market trends, growth factors, and opportunities4.2.2. Market size and forecast, by region4.2.3. Market analysis, by country4.3.300 mm4.3.1. Key market trends, growth factors, and opportunities4.3.2. Market size and forecast, by region4.3.3. Market analysis, by countryCHAPTER 5: silicon on insulator Market, BY wafer type5.1. Overview5.2. RF-SOI5.2.1. Key market trends, growth factors, and opportunities5.2.2. Market size and forecast, by region5.2.3. Market analysis, by country5.3. FD-SOI5.3.1. Key market trends, growth factors, and opportunities5.3.2. Market size and forecast, by region5.3.3. Market analysis, by country5.4. PD-SOI5.4.1. Key market trends, growth factors, and opportunities5.4.2. Market size and forecast, by region5.4.3. Market analysis, by country5.5. Others5.5.1. Key market trends, growth factors, and opportunities5.5.2. Market size and forecast, by region5.5.3. Market analysis, by countryCHAPTER 6: silicon on insulator Market, BY Technology6.1. Overview6.2. BESOI6.2.1. Key market trends, growth factors, and opportunities6.2.2. Market size and forecast, by region6.2.3. Market analysis, by country6.3. SiMOX6.3.1. Key market trends, growth factors, and opportunities6.3.2. Market size and forecast, by region6.3.3. Market analysis, by country6.4. Smart Cut6.4.1. Key market trends, growth factors, and opportunities6.4.2. Market size and forecast, by region6.4.3. Market analysis, by country6.5. ELTRAN6.5.1. Key market trends, growth factors, and opportunities6.5.2. Market size and forecast, by region6.5.3. Market analysis, by country6.6. SoS6.6.1. Key market trends, growth factors, and opportunities6.6.2. Market size and forecast, by region6.6.3. Market analysis, by countryCHAPTER 7: silicon on insulator Market, BY product7.1. Overview7.2. RF FEM7.2.1. Key market trends, growth factors, and opportunities7.2.2. Market size and forecast, by region7.2.3. Market analysis, by country7.3. MEMS7.3.1. Key market trends, growth factors, and opportunities7.3.2. Market size and forecast, by region7.3.3. Market analysis, by country7.4. Power7.4.1. Key market trends, growth factors, and opportunities7.4.2. Market size and forecast, by region7.4.3. Market analysis, by country7.5. Optical Communication7.5.1. Key market trends, growth factors, and opportunities7.5.2. Market size and forecast, by region7.5.3. Market analysis, by country7.6. Image Sensing7.6.1. Key market trends, growth factors, and opportunities7.6.2. Market size and forecast, by region7.6.3. Market analysis, by countryCHAPTER 8: silicon on insulator Market, BY Application8.1. Overview8.2. Consumer electronics8.2.1. Key market trends, growth factors, and opportunities8.2.2. Market size and forecast, by region8.2.3. Market analysis, by country8.3. Automotive8.3.1. Key market trends, growth factors, and opportunities8.3.2. Market size and forecast, by region8.3.3. Market analysis, by country8.4. Datacom & Telecom8.4.1. Key market trends, growth factors, and opportunities8.4.2. Market size and forecast, by region8.4.3. Market analysis, by country8.5. Industrial8.5.1. Key market trends, growth factors, and opportunities8.5.2. Market size and forecast, by region8.5.3. Market analysis, by country8.6. Photonics8.6.1. Key market trends, growth factors, and opportunities8.6.2. Market size and forecast, by region8.6.3. Market analysis, by country8.7. Others8.7.1. Key market trends, growth factors, and opportunities8.7.2. Market size and forecast, by region8.7.3. Market analysis, by countryCHAPTER 9: silicon on insulator Market, BY Region9.1. Overview9.2. North America9.3. Europe9.4. Asia-Pacific9.5. LAMEACHAPTER 10: COMPETITIVE LANDSCAPE10.1. Introduction10.1.1. Market player positioning, 201910.2. Competitive dashboard10.3. Competitive heatmap10.4. Key developments10.4.1. New product launches10.4.2. Collaborations10.4.3. Other DevelopmentsCHAPTER 11: COMPANY PROFILES11.1. TOWER SEMicONDUCTOR LTD.11.1.1. Company overview11.1.2. Key Executive11.1.3. Company snapshot11.1.4. Operating business segments11.1.5. Product portfolio11.1.6. R&D Expenditure11.1.7. Business performance11.1.8. Key strategic moves and developments11.2. GLOBAL WAFERS CO., LTD.11.2.1. Company overview11.2.2. Key Executive11.2.3. Company snapshot11.2.4. Operating business segments11.2.5. Product portfolio11.2.6. R&D Expenditure11.2.7. Business performance11.3. MagnaChip Semiconductor Corporation11.3.1. Company overview11.3.2. Key Executive11.3.3. Company snapshot11.3.4. Operating business segments11.3.5. Product portfolio11.3.6. R&D Expenditure11.3.7. Business performance11.3.8. Key strategic moves and developments11.4. MURATA MANUFACTURING COMPANY, LTD.11.4.1. Company overview11.4.2. Key Executive11.4.3. Company snapshot11.4.4. Operating business segments11.4.5. Product portfolio11.4.6. R&D Expenditure11.4.7. Business performance11.4.8. Key strategic moves and developments11.5. NXP Semiconductor11.5.1. Company overview11.5.2. Key Executives11.5.3. Company snapshot11.5.4. Product portfolio11.5.5. R&D Expenditure11.5.6. Business performance11.5.7. Key strategic moves and developments11.6. SHIN-ETSU CHEMicAL CO., LTD11.6.1. Company overview11.6.2. Key Executives11.6.3. Company snapshot11.6.4. Operating business segments11.6.5. Product portfolio11.6.6. R&D Expenditure11.6.7. Business performance11.6.8. Key strategic moves and developments11.7. Shanghai Simgui Technology Co., Ltd.11.7.1. Company overview11.7.2. Key Executive11.7.3. Company snapshot11.7.4. Product portfolio11.8. Soitec11.8.1. Company overview11.8.2. Key Executive11.8.3. Company snapshot11.8.4. Operating business segments11.8.5. Product portfolio11.8.6. R&D Expenditure11.8.7. Business performance11.8.8. Key strategic moves and developments11.9. STMicroelectronics N. V.11.9.1. Company overview11.9.2. Key Executives11.9.3. Company snapshot11.9.4. Operating business segments11.9.5. Product portfolio11.9.6. R&D Expenditure11.9.7. Business performance11.9.8. Key strategic moves and developments11.10. SUMCO CORPORATION11.10.1. Company overview11.10.2. Key Executives11.10.3. Company snapshot11.10.4. Operating business segments11.10.5. Product portfolio11.10.6. R&D Expenditure11.10.7. Business performanceFor more information about this report visit https://www.researchandmarkets.com/r/8z071v CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
As Americans flock to vaccine sites nationwide, a collective sigh of relief is almost palpable. Yet, for some, despite the promise of protection from a deadly and unpredictable virus, the trauma of the past year is just now taking its toll. According to the Mental Health Index: U.S. Worker Edition, employees ages 40-59 are experiencing worrisome declines in mental health over the last few months. Risk of PTSD has increased 51% since January; and planning, which impacts decisiveness, is down 10% in March 2021. Further, risk of general anxiety is 86% higher than before the pandemic. Findings also reveal that these employees have increased feelings of panic (9%) and fear (12%) when compared to before COVID-19.
Intellicheck has announced the appointment of Bruce Ackerman as Senior Vice President of Sales and David Andrews as Vice President of Marketing.